Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.15M$2.15Mderived−26.4% vs Q4 2022 Net Income-$1.23M-$1.23MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$79,158N/M Operating Incomederived-$1,184,491N/M Operating Cash Flowderived-$22,323N/M Margins · derivedGross margin-3.7%−5.1 pt vs Q4 2022
Operating margin-55.1%−15.1 pt vs Q4 2022
Net margin-57.3%−14.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end